

Salvatore Corallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5588721/publications.pdf>

Version: 2024-02-01

43
papers

1,088
citations

567281

15
h-index

434195

31
g-index

43
all docs

43
docs citations

43
times ranked

1663
citing authors

#	ARTICLE	IF	CITATIONS
1	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	6.4	15
2	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	3.7	3
3	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021, 107, 150-159.	1.1	8
4	FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis. <i>Oncologist</i> , 2021, 26, 302-309.	3.7	9
5	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	2.8	12
6	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	2.2	4
7	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
8	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	7.0	14
9	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
10	Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. <i>ESMO Open</i> , 2021, 6, 100246.	4.5	11
11	The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases. <i>Scientific Reports</i> , 2020, 10, 10871.	3.3	10
12	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 683.	2.6	53
13	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	3.7	26
14	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020, 123, 403-409.	6.4	93
15	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	2.8	10
16	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	10.7	196
17	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , 2020, 135, 230-239.	2.8	11
18	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	3.7	29

#	ARTICLE	IF	CITATIONS
19	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	3.7	14
20	Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 547.	7.1	32
21	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	2.3	16
22	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1017-1024.	7.0	22
23	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173.	3.8	7
24	Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	3.0	11
25	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1268.	7.1	70
26	Health-related quality of life in <i>RAS</i> wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. <i>Annals of Oncology</i> , 2019, 30, iv115.	1.2	1
27	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 3099-3110.	1.6	65
28	Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 2858.	3.3	38
29	Lack of Benefit From Anti-EGFR Treatment in <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.3	7
30	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei. <i>Clinical Colorectal Cancer</i> , 2019, 18, e179-e190.	2.3	12
31	Class 1, 2, and 3 <i>BRAF</i> -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	7.0	67
32	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	2.6	12
33	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	2.8	9
34	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
35	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
36	Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei. <i>Annals of Oncology</i> , 2018, 29, viii194.	1.2	0

#	ARTICLE	IF	CITATIONS
37	First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study. <i>Annals of Oncology</i> , 2018, 29, v106.	1.2	0
38	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	1.2	32
39	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3505-3505.	1.6	23
40	Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation. , 2018, , .		3
41	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 153-161.	3.6	31
42	Adequacy of EBUS-TBNA specimens for molecular testing in lung adenocarcinoma. , 2017, , .		0
43	DEBIRI and capecitabine in refractory prevalently liver metastases of colorectal cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 724-724.	1.6	0